News > Personalised melanoma vaccines prolong survival in largest trial yet
Personalised melanoma vaccines prolong survival in largest trial yet
15/12/2022 09:37 PM | Click to read full article
The trial was carried out by the pharmaceutical company Moderna, which made the personalised cancer vaccines using similar mRNA technology to its covid-19 vaccines. The trial was made up of 157 people in the US and Australia who had recently undergone surgery to remove melanomas but were at a high risk of developing new tumours because some cancer cells had spread to other parts of their body.
